Patterns of corticosteroid use among remdesivir and matched patients and associated clinical outcomes in hospitalized COVID-19 patients

被引:0
|
作者
Papic, Ivan [1 ]
Bistrovic, Petra [2 ]
Keres, Tatjana [3 ]
Hadziabdic, Maja Ortner [4 ]
Lucijanic, Marko [5 ,6 ,7 ]
机构
[1] Univ Hosp Dubrava, Pharm Dept, Zagreb, Croatia
[2] Univ Hosp Dubrava, Cardiol Dept, Zagreb, Croatia
[3] Univ Hosp Dubrava, Intens Care Dept, Zagreb, Croatia
[4] Univ Zagreb, Fac Pharm & Biochem, Ctr Appl Pharm, Zagreb, Croatia
[5] Univ Hosp Dubrava, Hematol Dept, Av Gojka Suska 6, Zagreb, Croatia
[6] Univ Zagreb, Sch Med, Internal Med Dept, Zagreb, Croatia
[7] Univ Zagreb, Sch Med, Zagreb 10000, Croatia
关键词
Remdesivir; corticosteroids; prognosis; dexamethasone; methylprednisolone; prednisone;
D O I
10.1080/14656566.2024.2320255
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
IntroductionWe aimed to investigate patterns of corticosteroid use and their relationship with remdesivir use and clinical outcomes in a large real-life cohort of COVID-19 patients treated in a tertiary-level institution.MethodsWe retrospectively analyzed a total of 1558 severe and critical COVID-19 patients, including 779 patients treated with remdesivir and 779 matched control patients.ResultsA total of 167 (10.7%) patients received none, 710 (45.6%) low, 539 (34.6%) high, and 142 (9.1%) very high corticosteroid doses. Patients treated with remdesivir had significantly longer exposure to corticosteroids, received higher average and maximal daily doses, and cumulative corticosteroid doses. In the multivariate analysis remdesivir use, lower cumulative comorbidity burden, higher severity of COVID-19 symptoms, and mechanical ventilation were recognized as mutually independent predictors of the use of higher corticosteroid doses. Higher corticosteroid doses were associated with significantly increased mortality.Among non-remdesivir treated patients, there was a U-shaped relationship between maximal daily corticosteroid dose and mortality. Among remdesivir treated patients gradual increase in mortality with increasing corticosteroid doses was observed.ResultsA total of 167 (10.7%) patients received none, 710 (45.6%) low, 539 (34.6%) high, and 142 (9.1%) very high corticosteroid doses. Patients treated with remdesivir had significantly longer exposure to corticosteroids, received higher average and maximal daily doses, and cumulative corticosteroid doses. In the multivariate analysis remdesivir use, lower cumulative comorbidity burden, higher severity of COVID-19 symptoms, and mechanical ventilation were recognized as mutually independent predictors of the use of higher corticosteroid doses. Higher corticosteroid doses were associated with significantly increased mortality.Among non-remdesivir treated patients, there was a U-shaped relationship between maximal daily corticosteroid dose and mortality. Among remdesivir treated patients gradual increase in mortality with increasing corticosteroid doses was observed.ConclusionPatterns of corticosteroid use differ regarding the use of remdesivir and may moderate its association with survival among severe and critical COVID-19 patients.
引用
收藏
页码:215 / 222
页数:8
相关论文
共 50 条
  • [1] REMDESIVIR USE IN HOSPITALIZED COVID-19 PATIENTS
    Said, Mohamed Ziad-M
    Ramirez, Claudia
    Almaguer, Angelica
    Emeaba, Ndiya
    Vazquez-Suarez, Amando A.
    Nieto, Fernando Loyola
    Girn, Tarunveer
    Mamki, Patience
    Burton, Diamond
    Valencia, Ired
    Silva-Llanas, Viana
    Texidor-Enchautegui, Jovana
    Gonzalez, Jesus Salvador
    Bhalla, Sushen
    Martini-Medina, Daniel
    Canete-Cruz, Ailine
    Akinwale, David
    Hussaini, Najia
    Varon, Joseph
    CRITICAL CARE MEDICINE, 2023, 51 (01) : 208 - 208
  • [2] Probiotics use is associated with improved clinical outcomes among hospitalized patients with COVID-19
    Zhang, Lina
    Han, Huanqin
    Li, Xuan
    Chen, Caozhen
    Xie, Xiaobing
    Su, Guomei
    Ye, Shicai
    Wang, Cuili
    He, Qing
    Wang, Fang
    Huang, Fang
    Wang, Zhaoqin
    Wu, Jiayuan
    Lai, Tianwen
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2021, 14
  • [3] Comparison of Safety and Outcomes Related to Remdesivir Use Among Dialysis Patients Hospitalized with COVID-19
    Zaki, Kirollos E.
    Huang, Cheng-Wei
    Zhou, Hui
    Chung, Joanie
    Selevan, David C.
    Rutkowski, Mark P.
    Sim, John J.
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2021, 32 (10): : 102 - 102
  • [4] Remdesivir in hospitalized COVID-19 Patients
    Thiem, Helena
    GESUNDHEITSOEKONOMIE UND QUALITAETSMANAGEMENT, 2022, 27 (03): : 111 - +
  • [5] Early Use of Remdesivir in Patients Hospitalized With COVID-19 Improves Clinical Outcomes A Retrospective Observational Study
    Paranjape, Neha
    Husain, Mir
    Priestley, Jennifer
    Koonjah, Yashila
    Watts, Christopher
    Havlik, Joseph
    INFECTIOUS DISEASES IN CLINICAL PRACTICE, 2021, 29 (05) : E282 - E286
  • [6] Clinical Features and Outcomes Associated with Bronchial Asthma Among COVID-19 Hospitalized Patients
    Diaz, Miguel Angel
    Catalan-Caceres, Nelly
    Beauperthuy, Thais
    Domingo, Carlos
    Ibanez, Ethel
    Morata, Carmen
    De Diego, Alfredo
    JOURNAL OF ASTHMA AND ALLERGY, 2022, 15 : 775 - 781
  • [7] The prevalence of hyperkalemia and associated clinical characteristics and outcomes among hospitalized COVID-19 patients
    Agiro, Abiy
    Moon, Rena
    Rosenthal, Ning
    Brown, Harold
    Legg, Randall
    Amin, Alpesh
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2021, 30 : 106 - 106
  • [8] Corticosteroid and Biologic Use Not Associated With Adverse Outcomes for Inflammatory Bowel Disease Patients Hospitalized With COVID-19
    Sultan, Keith
    Durbin, Laura
    Bhardwaj, Richa
    Mackey, James
    Becher, Noah
    Abureesh, Mohammad
    Lakhani, Komal
    Mone, Anjali
    Abergel, Jeffrey
    Trindade, Arvind
    Korelitz, Burton I.
    Swaminath, Arun
    GASTROENTEROLOGY RESEARCH, 2021, 14 (06) : 324 - 333
  • [9] The effect of remdesivir for the treatment of COVID-19 on mortality among hospitalized patients
    Breskin, Alexander
    Wiener, Catherine
    Brookhart, M. Alan
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 : 96 - 96
  • [10] Comparison of safety and outcomes related to remdesivir treatment among dialysis patients hospitalized with COVID-19
    Zaki, Kirollos E.
    Huang, Cheng-Wei
    Zhou, Hui
    Chung, Joanie
    Selevan, David C.
    Rutkowski, Mark P.
    Sim, John J.
    CLINICAL KIDNEY JOURNAL, 2022, 15 (11) : 2056 - 2062